Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients-Reference-Cited by-同舟云学术

Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients

Published:2001-03-14 Issue:2 Volume:7 Page:146-153
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

Philipp C. S.,

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2516.2001.00482.x/fullpdf

Reference25 articles.

1. Viral safety of a new highly purified factor VIII (Octate);Biesert;J Med Virol,1996

2. Elimination of non-lipid enveloped viruses in the preparation of a monoclonal antibody purified and pasteurized factor VIII concentrate (Monoclate-P®);Chandra;Blood,1995

3. Centeon Data on File TM 1998

4. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

5. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients;Fletcher;Br Med J,1983

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of previously untreated patient studies in understanding the development of FVIII inhibitors;Haemophilia;2015-08-27

2. Management of Haemophilia A-Inhibitor Patients: Clinical and Regulatory Perspectives;Clinical Reviews in Allergy & Immunology;2009-01-28

3. Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?;British Journal of Haematology;2002-10-30

4. Advances in the treatment of von Willebrand disease;Seminars in Hematology;2001-10

5. Advances in the treatment of von Willebrand disease;Seminars in Hematology;2001-10